Skip to main content
. 2018 Aug 8;9:877. doi: 10.3389/fphar.2018.00877

FIGURE 1.

FIGURE 1

Rapamycin induces de novo synthesis of CTGF in HPCs. (A) LE/6 and WB-F344 cells was treated with Rapamycin at indicated concentrations for 6 h. Lysates were subjected to Western blot analysis with antibodies against CTGF. β-actin was used as a loading control; (B) LE/6 and WB-F344 cells was stimulated with rapamycin (10 nM) for the indicated times before cells were harvested for immunoblotting analysis against CTGF. β-actin was used as a loading control; (C) LE/6 and WB-F344 cells was treated with Rapamycin (10 nM) for 6 h, and the relative CTGF expression was analyzed by qRT-PCR. Result was means ± SD of triplicate measurements. Experiment was repeated three times; ∗∗p < 0.01, ∗∗∗p < 0.001; (D) LE/6 and WB-F344 cells was co-transfected with pRL-TK and CTGF-luc plasmids and then treated with Rapamycin for 16 h. Luciferase activity was normalized to renilla luciferase activity. Results showed as means ± SD of triplicate measurements. ∗p < 0.05, ∗∗p < 0.01 compared with the control; (E) LE/6 and WB-F344 cells was treated with Rapamycin (10 nM) and cycloheximide (10 μg/mL) as indicated for 6 h. Lysates were subjected to Western blot analysis with antibodies against indicated proteins. β-actin was used as a loading control.